Eltrombopag/Eltrombopag’s remarkable effect in the treatment of various blood diseases

Eltrombopag/Eltrombopag, also known as Eltrombopag, is a drug that can effectively promote platelet production. It is widely used to treat immune thrombocytopenia (ITP), hepatitis C-related thrombocytopenia, and severe aplastic anemia (SAA). During treatment, the patient's physical condition is monitored through routine liver function and vision tests.

1. The application effect of eltrombopag in immune thrombocytopenia

1. Adult ITP patients:

Eltrombopag showed significant efficacy in two studies involving311 adult patients with ITP who had failed or relapsed from prior treatment. In the first study, 59% of patients taking eltrombopag had an improvement in platelet counts to at least 50,000 per microliter after six weeks of treatment, a level considered sufficient to prevent bleeding complications. The second study showed that over a six-month treatment period, patients taking eltrombopag were eight times more likely to reach their target platelet count than those taking a placebo.

Further data analysis showed that the efficacy of eltrombopag was not affected by the length of time since the patient was diagnosedITP. In a sample of nearly 400 patients, eltrombopag had about the same effect in raising platelet counts whether patients were diagnosed with ITP within 6 months of treatment or 6 months before.

2. Pediatric ITP patients:

In childrenEltrombopag also shows its superiority in patients with ITP. A major 13-week study showed that eltrombopag was more effective at raising platelet counts than placebo. Between weeks 5 and 12 of the study, approximately 40% of pediatric patients taking eltrombopag were able to maintain platelet counts above 50,000 per microliter for at least 6 out of 8 weeks. An extension of the study also confirmed that eltrombopag was effective in maintaining adequate platelet levels over the long term.

2. The efficacy of eltrombopag in hepatitis C-related thrombocytopenia

Eltrombopag was used to help people with hepatitis C initiate and maintain antiviral treatment in two studies involving1,441 adult patients. These patients initially had platelet counts that were too low (less than 75,000 per microliter) to initiate antiviral therapy directly. The results showed that six months after treatment ended, a significantly higher proportion of patients taking eltrombopag tested negative for the hepatitis C virus than those taking a placebo (23% in the first study and 19% in the second study).

3. The role of eltrombopag in the treatment of severe aplastic anemia

In a study to treat severe aplastic anemia, 43 patients received eltrombopag. The primary efficacy measure was the number of patients who responded to the drug after 12 or 16 weeks of treatment, meaning their platelet, red blood cell or white blood cell counts were maintained above a preset level. Results showed that 40% of patients responded to treatment after 12 weeks, with 65% of patients having platelet counts that increased by at least 20,000 per microliter or remained stable without the need for transfusions. Preliminary data from another supporting study are consistent with the main findings, showing that 46% of patients had a positive response to eltrombopag treatment after 12 weeks.